caa a22 4500 606241264 CHVBK 20210128101312.0 cr unu---uuuuu 210128e20150901xx s 000 0 eng 10.1007/s00508-014-0688-0 doi (NATIONALLICENCE)springer-10.1007/s00508-014-0688-0 Štuhec Matej Department for Clinical Pharmacy, Psychiatric Hospital Ormož, Ptujska Cesta 33, Ormož, Slovenia aut Excessive sweating induced by interaction between agomelatine and duloxetine hydrochloride: case report and review of the literature [Elektronische Daten] [Matej Štuhec] Exzessives, durch eine Interaktion zwischen Agomelatin und Duloxetin Hydrochlorid ausgelöstes Schwitzen - Fallbericht und Übersicht über die Literatur Summary: Objective: In this case report, we describe a case in which the clinical pharmacy team was asked to provide recommendations on possible continued use of combination antidepressants in a 62-year-old Slovenian female patient with major depressive disorder following agomelatine and duloxetine hydrochloride-induced excessive sweating. When agomelatine was administered as an additional treatment, drug-induced excessive sweating was observed after a daily intake of 90mg of duloxetine hydrochloride and 25mg of agomelatine. After thorough discussion, it was decided not to rechallenge with agomelatine because of the serious adverse effect. After agomelatine discontinuation and switching to trazodone, symptoms immediately improved. Discussion: Duloxetine hydrochloride-induced sweating has been reported frequently, but excessive sweating induced by agomelatine and duloxetine hydrochloride has not been reported in the literature. The adverse effect was determined by a clinical pharmacist using the Naranjo probability scale and was probably associated with agomelatine use (6 points) and possibly associated with duloxetine hydrochloride use (4 points). The exact mechanism for this adverse effect in this patient is not known, but we believe that a pharmacodynamic drug-drug interaction between agomelatine and duloxetine hydrochloride had occurred. Conclusion: Such a case has not yet been described in literature; however, an adverse effect associated with drug-drug interaction can occur, as this report clearly demonstrates. The benefits of this antidepressant combination need to be carefully balanced with the risks associated with its use. This case report also highlights the increased potential for adverse reactions when prescribing antidepressant combinations and importance of clinical pharmacists' involvement in the psychiatric patients' pharmacotherapy. Springer-Verlag Wien, 2014 Agomelatine nationallicence Sweating nationallicence Duloxetine hydrochloride nationallicence Drug-drug interaction nationallicence Psychiatry nationallicence Clinical pharmacy nationallicence Agomelatin nationallicence Schwitzen nationallicence Duloxetine Hydrochlorid nationallicence Medikamenteninteraktion nationallicence Psychiatrie nationallicence Klinische Pharmakologie nationallicence Wiener klinische Wochenschrift Springer Vienna 127/17-18(2015-09-01), 703-706 0043-5325 127:17-18<703 2015 127 508 https://doi.org/10.1007/s00508-014-0688-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00508-014-0688-0 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Štuhec Matej Department for Clinical Pharmacy, Psychiatric Hospital Ormož, Ptujska Cesta 33, Ormož, Slovenia aut NATIONALLICENCE 773 0- Wiener klinische Wochenschrift Springer Vienna 127/17-18(2015-09-01), 703-706 0043-5325 127:17-18<703 2015 127 508